80 related articles for article (PubMed ID: 10206310)
1. Evaluation of screening for nasopharyngeal carcinoma: trial design using Markov chain models.
Chen HH; Prevost TC; Duffy SW
Br J Cancer; 1999 Apr; 79(11-12):1894-900. PubMed ID: 10206310
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of a selective screening for colorectal carcinoma: the Taiwan Multicenter Cancer Screening (TAMCAS) project.
Chen TH; Yen MF; Lai MS; Koong SL; Wang CY; Wong JM; Prevost TC; Duffy SW
Cancer; 1999 Oct; 86(7):1116-28. PubMed ID: 10506694
[TBL] [Abstract][Full Text] [Related]
3. Complementary serum test of antibodies to Epstein-Barr virus nuclear antigen-1 and early antigen: a possible alternative for primary screening of nasopharyngeal carcinoma.
Chang KP; Hsu CL; Chang YL; Tsang NM; Chen CK; Lee TJ; Tsao KC; Huang CG; Chang YS; Yu JS; Hao SP
Oral Oncol; 2008 Aug; 44(8):784-92. PubMed ID: 18206420
[TBL] [Abstract][Full Text] [Related]
4. Screening for family members of patients with nasopharyngeal carcinoma.
Ng WT; Yau TK; Yung RW; Sze WM; Tsang AH; Law AL; Lee AW
Int J Cancer; 2005 Mar; 113(6):998-1001. PubMed ID: 15515016
[TBL] [Abstract][Full Text] [Related]
5. Colorectal cancer screening with faecal occult blood test within a multiple disease screening programme: an experience from Keelung, Taiwan.
Yang KC; Liao CS; Chiu YH; Yen AM; Chen TH
J Med Screen; 2006; 13 Suppl 1():S8-13. PubMed ID: 17227635
[TBL] [Abstract][Full Text] [Related]
6. Nasopharyngeal carcinoma research in Hong Kong in the past decade.
Sham JS; Wei W; Ng MH; Nicholls J; Choy D
Chin Med J (Engl); 1997 Nov; 110(11):826-31. PubMed ID: 9772411
[TBL] [Abstract][Full Text] [Related]
7. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma.
Shao JY; Li YH; Gao HY; Wu QL; Cui NJ; Zhang L; Cheng G; Hu LF; Ernberg I; Zeng YX
Cancer; 2004 Mar; 100(6):1162-70. PubMed ID: 15022282
[TBL] [Abstract][Full Text] [Related]
8. Nonparametric estimation of asymptomatic duration from a randomized prospective cancer screening trial.
Shen Y; Huang X
Biometrics; 2005 Dec; 61(4):992-9. PubMed ID: 16401272
[TBL] [Abstract][Full Text] [Related]
9. Loss of heterozygosity and its correlation with clinical outcome and Epstein-Barr virus infection in nasopharyngeal carcinoma.
Shao JY; Huang XM; Yu XJ; Huang LX; Wu QL; Xia JC; Wang HY; Feng QS; Ren ZF; Ernberg I; Hu LF; Zeng YX
Anticancer Res; 2001; 21(4B):3021-9. PubMed ID: 11712805
[TBL] [Abstract][Full Text] [Related]
10. Screening nasopharyngeal carcinoma by detection of the latent membrane protein 1 (LMP-1) gene with nasopharyngeal swabs.
Hao SP; Tsang NM; Chang KP
Cancer; 2003 Apr; 97(8):1909-13. PubMed ID: 12673717
[TBL] [Abstract][Full Text] [Related]
11. Plasma Epstein-Barr virus immunoglobulin A and DNA for nasopharyngeal carcinoma screening in the United States.
O TM; Yu G; Hu K; Li JC
Otolaryngol Head Neck Surg; 2007 Jun; 136(6):992-7. PubMed ID: 17547994
[TBL] [Abstract][Full Text] [Related]
12. Outcome of patients with positive Epstein-Barr virus serologic status in the absence of nasopharyngeal carcinoma in Hong Kong.
Lo S; Ho WK; Wei WI
Arch Otolaryngol Head Neck Surg; 2004 Jun; 130(6):770-2. PubMed ID: 15210561
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of organized versus opportunistic cervical cytology screening in Hong Kong.
Kim JJ; Leung GM; Woo PP; Goldie SJ
J Public Health (Oxf); 2004 Jun; 26(2):130-7. PubMed ID: 15284314
[TBL] [Abstract][Full Text] [Related]
14. Epstein-Barr virus serology in early detection and screening of nasopharyngeal carcinoma.
Ng MH; Chan KH; Ng SP; Zong YS
Ai Zheng; 2006 Feb; 25(2):250-6. PubMed ID: 16480597
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic value of Epstein-Barr viral serology in nasopharyngeal carcinoma.
Low WK; Leong JL; Goh YH; Fong KW
Otolaryngol Head Neck Surg; 2000 Oct; 123(4):505-7. PubMed ID: 11020195
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Epstein-Barr virus DNA level in plasma, peripheral blood cell and tumor tissue in nasopharyngeal carcinoma.
Shao JY; Zhang Y; Li YH; Gao HY; Feng HX; Wu QL; Cui NJ; Cheng G; Hu B; Hu LF; Ernberg I; Zeng YX
Anticancer Res; 2004; 24(6):4059-66. PubMed ID: 15736452
[TBL] [Abstract][Full Text] [Related]
17. Pretherapy quantitative measurement of circulating Epstein-Barr virus DNA is predictive of posttherapy distant failure in patients with early-stage nasopharyngeal carcinoma of undifferentiated type.
Leung SF; Chan AT; Zee B; Ma B; Chan LY; Johnson PJ; Lo YM
Cancer; 2003 Jul; 98(2):288-91. PubMed ID: 12872347
[TBL] [Abstract][Full Text] [Related]
18. Assessing chronic disease progression using non-homogeneous exponential regression Markov models: an illustration using a selective breast cancer screening in Taiwan.
Hsieh HJ; Chen TH; Chang SH
Stat Med; 2002 Nov; 21(22):3369-82. PubMed ID: 12407678
[TBL] [Abstract][Full Text] [Related]
19. Analytical decision model for sample size and effectiveness projections for use in planning a population-based randomized controlled trial of colorectal cancer screening.
Chiu SY; Malila N; Yen AM; Anttila A; Hakama M; Chen HH
J Eval Clin Pract; 2011 Feb; 17(1):123-9. PubMed ID: 20831662
[TBL] [Abstract][Full Text] [Related]
20. The effect of misclassification in screening trials: a simulation study.
Obuchowski NA; Lieber ML
Contemp Clin Trials; 2008 Mar; 29(2):125-35. PubMed ID: 17613281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
